Eli Lilly & Co.'s stock, consistently trading above $1,000 per share due to the success of its obesity drugs, is now seen by some analysts as a prime candidate for a stock split.

Shares of Eli Lilly & Co. fell in premarket trading after new industry prescription data for its blockbuster obesity drug Zepbound disappointed Wall Street investors.

Analysts have expressed conflicting sentiments regarding several healthcare companies, including Pacific Edge Limited, Kura Oncology, and Eli Lilly & Co. Their differing opinions reflect varied outlooks on these firms.

Eli Lilly & Co. is sponsoring an ESPN2 reunion special celebrating the heroic coach Pat Summitt, aiming to find new ways to tell medical stories and connect with audiences beyond traditional commercials.

Early performance of Novo Nordisk's Wegovy pill is prompting investors to reconsider Eli Lilly & Co.'s previously assumed dominance in the GLP-1 pill market.